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relationships (KER). Although this approach to formalize 
mechanistic toxicological information only started in 2010, 
over 200 AOPs have already been established. At this stage, 
new requirements arise, such as the need for harmonization 
and re-assessment, for continuous updating, as well as for 
alerting about pitfalls, misuses and limits of applicability. 
Abstract Adverse outcome pathways (AOPs) are a recent 
toxicological construct that connects, in a formalized, trans-
parent and quality-controlled way, mechanistic information 
to apical endpoints for regulatory purposes. AOP links a 
molecular initiating event (MIE) to the adverse outcome 
(AO) via key events (KE), in a way specified by key event 
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In this review, the history of the AOP concept and its most 
prominent strengths are discussed, including the advantages 
of a formalized approach, the systematic collection of weight 
of evidence, the linkage of mechanisms to apical end points, 
the examination of the plausibility of epidemiological data, 
the identification of critical knowledge gaps and the design 
of mechanistic test methods. To prepare the ground for a 
broadened and appropriate use of AOPs, some widespread 
misconceptions are explained. Moreover, potential weak-
nesses and shortcomings of the current AOP rule set are 
addressed (1) to facilitate the discussion on its further evo-
lution and (2) to better define appropriate vs. less suitable 
application areas. Exemplary toxicological studies are pre-
sented to discuss the linearity assumptions of AOP, the man-
agement of event modifiers and compensatory mechanisms, 
and whether a separation of toxicodynamics from toxicoki-
netics including metabolism is possible in the framework 
of pathway plasticity. Suggestions on how to compromise 
between different needs of AOP stakeholders have been 
added. A clear definition of open questions and limitations 
is provided to encourage further progress in the field.
Keywords Regulatory toxicology · Systems biology · 
Multi-scale integration · Computational toxicology · 
Interspecies extrapolation · Metabolism · Pathway 
unidirectionality · Liver fibrosis · Paracetamol · CCl4 · 
Vinyl acetate · Tumor promotion · Binning of events · 




The adverse outcome pathway (AOP) concept (Ankley et al. 
2010) has attracted a large amount of attention in recent 
years, with more than 200 articles published on the issue 
in less than a decade. An AOP is defined as a sequence of 
events that begins with a molecular initiating event (MIE; 
e.g., inhibition of an enzyme or formation of DNA adducts) 
(Fig. 1). It progresses through a series of key events (KE) 
that define given cellular states. Such key events can be 
alterations of metabolic pathway, signaling events as well 
as modifications of organelles or cell functions (such as cell 
cycle control). Notably, an AOP may also be defined even 
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though the MIE is not exactly known, as long as there is 
at least one clearly defined KE. Finally, the AOP leads to 
an adverse outcome (AO), i.e., a classical apical end point 
as used traditionally for hazard evaluation and risk assess-
ment. According to OECD guidance (Guidance document on 
developing and assessing adverse outcome pathways 2017; 
Users’ handbook supplement to the guidance document for 
developing and assessing AOPs 2017), each AOP should 
have one MIE and one AO, but there is no limitation in 
the number of KEs. Examples of AO include liver fibrosis, 
defined types of cancer, skin sensitization or parkinsonian-
type motor deficits (OECD guidance document 2013). In 
an ecotoxicological context, typical AOs address reduced 
generalized fitness or a decline in reproductive success. 
One of the main purposes of AOPs is to connect existing 
knowledge on mechanisms of toxicity (in the form of KE) 
in a controlled and transparent weight of evidence process 
to apical end points (AO). The overall objective is to support 
regulatory decision-making, such as hazard identification 
and risk assessment, by formally describing the key events 
leading to an AO. This may pave the way to the use of KE-
related end points for decision-making. These surrogate end 
points may be used in addition to classical apical end points 
to strengthen the rationale of predictions and decisions or 
they may in future even be used instead of classical end 
points, as soon as the causal relationship of KEs and AO is 
sufficiently established. As such, the AOP concept can be 
regarded as a knowledge management tool that facilitates 
the use of mechanistic knowledge for regulatory purposes 
in toxicology and ecotoxicology. In this article, members of 
the EU-ToxRisk consortium and other experts in the field 
collected and analyzed information on the history of the 
AOP concept, the most prominent strengths, advantages 
and limitations, as well as possible ways to overcome such 
limitations.
Conceptions and misconceptions concerning AOPs
The AOP concept is a relatively new tool and as such pro-
vides numerous opportunities (Table 1). As always in such 
situations, it is important to have a good understanding of the 
concept to make the right use of it, i.e., to use it in situations 
in which it is well suited and to be careful of not overusing 
it in situations that have shortcomings. The concept also 
allows the development and optimization of new applica-
tions on the basis of both the understanding of the strengths 
and limitations of the AOP construct and on the experience 
gained from its use. To exemplify this, one may think of an 
AOP as a pair of plyers. They may be used to pull out a nail. 
A completely different, but also perfect use would be to turn, 
e.g., a nut. As the plyers are made of steel, they may also be 
used to hammer in a nail, or as a lever to wedge something 
away, but this would be less ideal and there would be better 
tools for such applications. Plyers also look a bit like scis-
sors, but they obviously have a different function.
AOPs are not signaling pathways. AOPs look to some 
extent like a drawing of a signaling pathway and share some 
of its features, but there are also important differences. One 
difference is the perspective taken. A classical signaling 
pathway starts at the signal initiation, and then often leads 
to signal amplification and splitting to arrive at multiple tar-
gets. Likewise, many academic researchers in the field of 
molecular toxicology are also interested in the initial target 
of a toxicant (e.g., the Ah receptor) and then follow the vari-
ous possible downstream consequences, but the exact link to 
an AO is often unclear. The AOP concept takes the opposite 
perspective. The anchoring point is the AO and each KE is 
examined concerning its relevance and necessity for the AO. 
A major intention is to link earlier KEs of an AOP to the AO, 
even if the starting point is unknown or some intermediate 
KEs are not (yet) fully understood.
AOPs are compound agnostic. AOPs describe a sequence 
of biological events, and the transitions from event to event 
that lead to an AO. This is independent of any specific chem-
ical. Thus, AOPs do not describe the mode of action of a 
chemical. However, a chemical may activate a specific AOP 
by provoking the MIE, or it may be used to provide empiri-
cal evidence for the existence of an AOP.
AOPs describe toxicodynamics, not toxicokinetics and 
therefore not risk. As AOPs are ‘compound agnostic’ they 
cannot incorporate a toxicokinetic phase. ADME properties 
and toxicokinetics cannot be uncoupled from specific chemi-
cals, while AOPs do not describe specific chemicals. Thus, 
AOPs as such cannot be used for risk assessment, but they 
describe a potential hazard, given that a specific compound 
at the concentration, which is reached at a relevant site, trig-
gers the MIE that activates the AOP. To use AOP informa-
tion for risk assessment, it should be imbedded together with 
Fig. 1  Schematic adverse outcome pathway (AOP) diagram. The 
schematic has been reproduced from the “Users’ handbook supple-
ment to the guidance document for developing and assessing AOPs 
(2017)” MIE molecular initiating event, KE key event, KER key event 
relationship, n number of KE of the AOP
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Table 1  Opportunities, shortcomings and open questions of the AOP concept
Characteristics of AOP Comments, examples and next steps
Opportunities/strengths
 Systematic collection of weight of evidence Introduction of ‘systematic reviews’ into toxicology (contrary to ‘narrative 
reviews’ and ‘cherry picking’ of evidence and mechanisms
 Sorting of information across multiple levels of organization The concept goes beyond classical ‘signaling’ pathways: bridging scales of 
organization from organelle to tissue/organism
 Link of mechanistic end points to apical end points Provides anchoring of mechanistic information to known apical end points: 
rationale for use of mechanistic data in regulatory contexts
 Convenient structure to visualize gaps of knowledge Useful to direct research needs; important for definition of uncertainty of mecha-
nistic information
 Consensus and certification process for canonical knowledge Knowledge aggregation by a broad community (Wiki-process; multiple review 
levels); provides plausibility to epidemiological data
 Allows to examine plausibility of epidemiological data Toxicological relevance of epidemiological data is strengthened, if robust AOPs 
explain how exposure to an agent can lead to an AO
 Guidance for use and design of mechanistic test methods The defined (causal, plausible, in part quantitative) links of key events (and 
respective assays) to adverse outcomes allow the use of key event tests for 
regulatory filtering, prioritization and decisions
Shortcomings (with respect to some potential applications)
 Linearity and unidirectionality rules Biology frequently uses feedforward and feedback
 Binning of large groups of events The MIE and KE of AOP often comprise dozens or even hundreds of individual 
biochemical events (e.g., inflammation, oxidative stress)
 Dealing with multiple hit events Several major pathologies require multiple hits and cannot be explained by one 
MIE
 How to deal with effect duration The time component is not reflected in the AOP scheme: it does not allow for a 
display of effect duration (or time window) required
 Neglect of event modifiers in graphical displays Although considered in the AOP handbook, and in the text parts, event modifiers 
cannot be displayed in the AOP scheme
 Dealing with compensatory mechanisms Considerations of the counter-regulation would need to be part of an AOP. 
Although considered for KER, display possibilities are limited
Alerts/open questions/misconceptions
 Defining non-toxicity Will the AOP system get comprehensive enough? Can we exclude with sufficient 
certainty activation of an AOP?
 Quantification of KE/KER; threshold setting Few thresholds fully known; hard to translate between in vitro and in vivo 
systems
 Review process The classical peer review process of journals is hardly suited for the review of 
such large documents. How can peer review be achieved?
 Quality assurance and validation How can AOP-based test batteries be validated? How good are the literature data 
used for AOP construction?
 One procedure for many different complexity levels Can one apply the same tools for different concepts as ‘aromatase inhibition’ 
(biochemical step) vs ‘steatosis’ (complex pathology)?
 Can toxicodynamics be separated from toxicokinetics? Is generation of reactive electrophiles part of ADME or of an AOP? Can the 
ADME phase always be separated from the AOP phase?
 How to deal with pathway plasticity In pathological situations, pathways themselves may change (bypass of KE, 
activation of steps not normally present)
 How to deal with species differences AOP describe species effects, but in practice most data are derived from rodent 
systems; species specificity is not always known
 AOPs are a snapshot of knowledge at a given time How is continuous updating ensured? Who decides on updates?
 Applicability fields AOPs are working tools, made for specific purposes. They cannot be used 
blindly outside their main field of application
 AOP vs systems biology models AOP can be more or less quantitative, but the concept is fundamentally different 
from systems biology models. AOP describe a transition of system states (not 
computable relationships between system modules)
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ADME considerations in an integrated approach to testing 
and assessment (IATA) of potential toxicants (Tollefsen 
et al. 2014).
AOPs are multi-scale data integration tools. Unlike many 
signaling pathways, AOPs span many levels of biological 
organization, from molecular over sub-cellular, cellular to 
organ and organism or, especially in the case of ecotoxicol-
ogy, even to the population level. The anchoring point is the 
AO relevant for the entire organism, while the MIE always 
is a molecular-level interaction. The AOP provides a scaffold 
to integrate data at such different scales, all with a general 
anchoring toward predictions of adverse outcomes. Notably, 
the rules of AOP construction not only allow integrating the 
data, but also provide a scaffold for sorting and weighing of 
contradictory or inconsistent data through a weight-of-evi-
dence process. In parallel, multi-scale quantitative models 
of toxicity are being developed (Obiol-Pardo et al. 2011).
AOPs are not intended to be molecularly detailed. It is 
often not clearly understood that AOPs are meant to describe 
a series of system states with some information on the transi-
tion between these states. Importantly, AOPs do not intend 
to comprehensively describe and quantify all system param-
eters. For practical reasons, often relatively superordinate 
processes, like mitochondrial function/dysfunction or intact/
disturbed calcium ion homeostasis, are used to describe the 
system states. This allows measurement of the system state 
with relatively simple and accessible methods, and thus has 
large practical advantages for predictive toxicology. In this 
sense, the concept differs from molecularly defined pathways 
of toxicity that require complex and comprehensive tools for 
their quantification (Kleensang et al. 2014; Sauer et al. 2015; 
Rahnenführer and Leist 2015). A mapping of molecular 
pathways of toxicity (Hartung and McBride 2011) by omics 
technologies instead of the literature compilation typically 
used for AOP was pioneered by the Human Toxome Project 
(Bouhifd et al. 2015; Hartung 2016).
AOPs are not systems biology models. While AOPs span 
multiple levels of biological organization, most systems biol-
ogy models still have large difficulties integrating different 
scales of organization, although some projects have recently 
achieved this goal (e.g., Ghallab et al. 2016; Schliess et al. 
2014; Drasdo et al. 2014; Carbonell et al. 2017). One of the 
practical limitations of systems biology models is that their 
establishment is usually labor intensive. A systems biol-
ogy model often has a network character, while AOPs are 
linear. Likewise, AOP networks, defined as sets of AOPs 
sharing at least one common element, are different from 
systems biology networks. AOP networks are intended to 
represent potential chemical effects. They are the tools for 
real-life application, unlike for individual AOPs. They may 
be focused on a single effect (e.g., steatosis), but describe 
all the pathways leading to this effect (e.g., multiple MIEs, 
crossing of KE). They provide information on interactions 
between AOPs and have the potential to reveal previously 
unknown links between biological pathways. Currently, it 
remains challenging to translate AOPs into mathematical 
models with ordinary differential equations, but research 
activities in this field are ongoing (Obiol-Pardo et al. 2011). 
Some mathematical models of AOPs appear possible and 
they may be regarded as transition stages to systems biology 
models (https://www.effectopedia.org/). It should be taken 
into account that system biology and AOPs are complemen-
tary tools. The AOP is intended for regulatory use, minimiz-
ing complexity to serve pragmatic decisions that so far are 
mainly based on animal studies. A future perspective is that 
systems biology models would be integrated into AOPs and 
informing risk assessment.
AOPs can provide plausibility for statistical associations. 
Most toxico-epidemiological research deals with statistical 
associations of chemical exposures and adverse outcomes. 
In most cases, it is difficult or impossible to clarify the cau-
sality of such correlations. One step toward this direction 
would be to provide a plausible link between exposure and 
adverse outcomes. AOPs, coupled to exposure and toxicoki-
netic information may provide such links by coupling expo-
sure to the triggering of an MIE. This approach may support 
environmental risk assessment.
AOPs can identify knowledge gaps, indicate testing flaws 
and may guide testing. An important practical application 
of AOPs is that they can guide the development of novel, 
mechanism based and often animal-free methods of hazard 
assessment. In this sense, the AOP framework constitutes a 
basis for the development of new non-animal test methods 
(i.e., in vitro methods anchored to KEs) and integrated test-
ing strategies (Hartung et al. 2013a, b; Rovida et al. 2015; 
Clippinger et al. 2016). It also provides biological context 
for mechanistic information from existing assays. In many 
cases, AOPs may be combined in AOP networks that share 
at least one KE. Analyses of these AOP networks can aid in 
the prioritization of assay development, whether the goal is 
to develop a single assay with predictive ability for multi-
ple outcomes or development of assays that are highly spe-
cific for a particular mode of action. Appropriate IATA or 
other types of integrated testing strategies (ITS), based on 
AOP (AOP networks) and toxicokinetic information, may 
in future use KE information to develop mechanistic assays 
(ideally based on human cells) to predict adverse effects for 
humans at high throughput and with low uncertainty related 
to interspecies extrapolations (Tollefsen et al. 2014; Jacobs 
et al. 2016; Paparella et al. 2017).
The history of the AOP concept
The AOP concept, introduced in 2010 as a tool to support 
risk assessment in ecotoxicology, is based on the long-stand-
ing principle that understanding the mechanisms linking 
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initial events to adverse effects is a key aspect of (predictive) 
toxicology (Ankley et al. 2010; Villeneuve et al. 2014a, b). 
Does this concept have a history beyond the short time span 
of the last 7 years? For more than 100 years, toxicologists 
have been well aware of the importance of understanding 
the mechanisms linking initial events, e.g., DNA damage or 
protein adducts, to adverse effects, such as cancer or fibrosis. 
Before 2010, such mechanistic explanations have not been 
termed AOP. Before that date, they were often mentioned 
as toxicity mechanism, mode of action or toxicity pathway 
and these terms included several key aspects of the current 
AOP concept. Likewise, the `biomarker` concept originally 
designed in the 1990s (Beliaeff and Burgeot 2002; Depledge 
1994; Huggett et al. 1992; McCarthy and Shugart 1990) 
contained major aspects of the current understanding of 
KEs. In fact, such thinking even goes back to the nineteenth 
century. For example, Louis Lewin (1850–1929) was aware 
of the advantages of classifying toxic compounds based on 
their pharmacologic or toxic mechanisms that led to adverse 
effects, as demonstrated by his grouping of psychoactive 
drugs into five categories (Lewin 1885, 1924). Although 
in Lewin’s time it was not yet feasible to study molecular 
mechanisms, the idea that a mechanism which explains an 
adverse effect allows a better classification than a simple 
description of toxic symptoms was already born. Since then, 
the improvement of risk evaluation by understanding of the 
toxicological mechanisms has been a focus of generations of 
toxicologists. A major milestone was the establishment and 
regulatory acceptance of the Ames test in the 80s of the last 
century. This test method would nowadays be coined as a 
KE assay for genotoxicity that predicts the AO of genotoxic 
carcinogenesis. A further key process was the work on KE 
tests relevant to skin sensitization. This resulted in the first 
AOP accepted for regulatory purposes, but the conceptual 
and experimental work was mostly planned and executed 
before the term AOP was coined. A further event preparing 
the ground for AOP was then the report of the US National 
Academy of Sciences in 2007, which suggested a reorien-
tation of toxicology, away from apical end points, moving 
toward mechanistic principles and introducing the toxicity 
pathways as a guiding principle (Leist et al. 2008; NRC 
2007).
In the light of this historical perspective, the question 
arises: What was new about the AOP concept? Three key 
aspects need to be mentioned here:
A first aspect is that AOP aims for a more formalized 
approach to risk assessment than previous mechanistic 
toxicology. Even the toxicity pathways of the NAS strat-
egy paper were still relatively little defined (Andersen and 
Krewski 2009, 2010). AOPs are by definition systematic, 
structured, quality controlled and weight of evidence based. 
One objection may be that this should apply to any toxi-
cological science and can therefore hardly be considered 
a novelty. Examples from other fields may help to convey 
the concept that novelty can indeed lie in the methodology 
and its stringency: Henry Ford was a great innovator in the 
automobile world, as was Steve Jobs for consumer electron-
ics. They both mainly perfected methods, based on already 
known basic knowledge. By analogy, there is a chance that 
the AOP concept will be pivotal for the application of mech-
anistic principles in risk assessment. So far, mechanistic data 
have rarely been considered in the assessment of industrial 
chemicals (with the notable exception of genotoxicity) and 
this has prevented the use of large amounts of available 
information by regulators.
A second important novelty is that large regulatory agen-
cies have adopted the concept of mechanistic toxicology 
(Leist et al. 2014; Edwards et al. 2016). The AOP concept 
is supported by the OECD, and this greatly facilitates its 
implementation into regulatory thinking. The consequence 
will be an integration of existing knowledge on toxic mecha-
nisms into regulatory procedures. A secondary consequence 
is that the European Commission and other funding agen-
cies have realized the need to support research projects that 
define and implement AOPs (Daneshian et al. 2016; Daston 
et al. 2015).
This leads to a third important issue: new ways of safety 
assessment are supported by the AOP concept. While mech-
anistic information traditionally has largely been seen as a 
supplementary for better explaining and rationalizing api-
cal end points of toxicity, the AOP concept now facilitates 
the use of a conclusive chain of mechanistic information 
alternative to a classical toxicological end point. This also 
means that new test systems, including in vitro approaches, 
are about to reach a new level of importance and recogni-
tion. It is very likely that an in vitro test battery or in silico 
methods, based on, or linked to key events in a relevant AOP, 
will be more likely to gain regulatory acceptance than tests 
not linked to or supported by an AOP. A first example of this 
was seen with the testing for dermal sensitization.
Further developments
As introduced here, the AOP concept has seen a dynamic 
development and as of June 2017 the AOP knowledge base 
maintained by the OECD lists 204 AOPs (with 1477 key 
events). An easy access to these AOPs is provided by the 
AOP-wiki (https://aopwiki.org/), where one may also follow 
the development stages, which are overseen by the Advi-
sory Group on Molecular Screening and Toxicogenomics 
(EAGMST). While these are positive developments, there is 
still a need to further advance and improve the AOP concept. 
It is essential to understand and clearly communicate how an 
AOP is defined and what it can be used for. On this founda-
tion, the AOP concept can be further refined and adapted to 
future needs that are not yet covered. Most importantly, open 
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questions are highlighted to guide future development and 
appropriate solutions to the limitations (Table 1).
Strengths and advantages of AOPs
Systematic collection of weight of evidence
The assembly of information on a scientific topic is often 
based on reviews written by experts in the field. Such 
reviews can be qualified according to their (1) contents, (2) 
form and (3) quality control procedure. Classical narrative 
reviews with contents similar to what may be found nowa-
days in an AOP have been common in toxicology for dec-
ades. An advantage of the AOP concept is that it now also 
provides very clear guidance on form and quality control. 
Strong emphasis is put on weight-of-evidence approaches 
to prevent personal bias. The large impact of such a formal 
process has been demonstrated in the field of medicine by 
the Cochrane collaboration and their ‘systematic reviews and 
protocols’ on health care. This concept has been adopted 
for toxicology by the Evidence-Based Toxicology Collabo-
ration (Hoffmann and Hartung 2006), which addresses the 
quality scoring of existing studies (Samuel et al. 2016) and 
systematic reviews (Stephens et al. 2016; Hoffmann et al. 
2017). The AOP guidelines have particularly optimized 
this procedure for toxicity pathways. Adherence to the rules 
should guarantee and may possibly improve the description 
of mechanisms of toxicity.
Certification process for canonical knowledge
In many disciplines of biomedical research, including toxi-
cology, the definition of canonical knowledge is an implicit 
process, i.e., it is embedded in the discipline without defined 
procedures. The collection of such knowledge is a slow pro-
cess that involves opinion leaders, textbook authors and oth-
ers. The definition and updating of the state of the art can 
take relatively long periods of time to reach acceptance, and 
this process has worked well for basic science. However, for 
applied and regulatory science, a more explicit and defini-
tive process is desirable. For regulators it is of high impor-
tance to have clarity on what is considered the scientific 
gold standard. Here, the process of AOP establishment and 
validation can be extremely helpful. The weight-of-evidence 
procedure, coupled to multiple levels of peer review, helps to 
define, certify and update canonical knowledge on a global 
(or at least OECD-wide) scale.
The view of an AOP database as a growing repository of 
canonical knowledge has implications for several areas. An 
application that springs to mind immediately is the support 
of mode-of-action information in regulatory dossiers, which 
will become more and more important. However, there are 
other areas of interest. For instance, an additional level of 
information can be added to read across approaches (Patle-
wicz et al. 2014; Ball et al. 2016) by comparing not only 
chemical structures of a group of compounds of interest, 
but also their cellular responses, i.e., by examining whether 
similar molecular targets and key events are involved (Zhu 
et al. 2016).
Sorting of information across multiple levels 
of organization
AOPs are particularly designed to allow integration of infor-
mation spanning from the molecular level, over sub-cellular, 
cellular and organ levels to the AO at the level of entire 
organisms (e.g., humans) or even populations or ecosys-
tems (e.g., in ecotoxicology). Many other approaches have 
particular strengths and track records in dealing with infor-
mation from a single organizational level, and past expe-
rience has shown that bridging of levels of complexity in 
organization is a particularly difficult scientific task, be it in 
physics, biology or toxicology. Although AOPs do not claim 
to provide all elements of a level-spanning pathway, they 
have the ambition to cover the main steps and to provide a 
clear rationality for the plausibility, causality and strength 
of linkage.
Link of mechanistic end points to apical end points
The issue above implies that mechanistic end points are 
connected to apical end points. On first sight, this does not 
appear to be a particularly new concept and advantage. How-
ever, taking into account the practical situation of mecha-
nistic toxicology, this apparently small point represents one 
of the most advantageous features of AOPs: There are some 
(but few) examples that mechanistic end points have been 
used in the past by regulators together with, or instead of, 
classical apical end points. They mostly refer to the area of 
genotoxicity and this area has shown how successful this 
concept can be. Countless 2-year rodent carcinogenicity 
bioassays have been avoided by the use of the Ames test 
or similar genotoxicity assays. These test methods are well 
accepted, because there is a well-accepted chain of events 
that links the mechanistic end point of DNA mutations to the 
apical end point of carcinogenesis. In contrast, in most other 
domains of toxicology, mechanistic end points have been 
used to a very limited extent for regulatory purposes. One 
of the reasons of this limited use is that the interpretation 
has often been difficult and the linkage of the mechanistic 
end point to the apical end point has not been sufficiently 
defined. For some areas, like developmental neurotoxicity 
(DNT), it has been widely assumed that mechanistic end 
points and in vitro models can never cover the in vivo com-
plexity (Kuegler et al. 2010; van Thriel et al. 2011). The 
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AOP concept now provides quality-controlled and formal-
ized tools to generate such linkages and therefore opens 
entirely new approaches to hazard assessment and eventually 
risk assessment. The possibility to regulate on the basis of 
mechanistic end points is a major driving force for in vitro 
toxicology and methods development.
Examination of the plausibility of epidemiological data
A particular version of the link of mechanistic end points 
and adverse outcomes has been examined by the Euro-
pean Food Safety Authority (EFSA; Ockleford et al. 2017; 
Pelkonen et al. 2017). In general, it is difficult to deal with 
and to react to epidemiologic data that suggest there is a 
statistical correlation between exposure to a chemical and 
certain adverse health outcomes. The causality of effects 
can hardly ever be proven on the basis of epidemiological 
approaches. However, one step ahead is the examination 
of whether there is at all a plausible link between a given 
chemical and the purported health outcome. The plausibility 
of such links is confirmed if there is an AOP that connects 
MIE triggered by chemicals at question to a relevant AO. 
In a further step, information from the AOPs may then be 
used (1) to examine whether the observed exposure would 
result in sufficiently high internal concentrations to trigger 
such an AOP, (2) to develop or recruit test methods that can 
quantify early KE or the MIE to provide testing based on 
easily accessible mechanistic end points and (3) to define 
gaps of knowledge that may be filled by dedicated research 
programs.
Visualization of knowledge gaps
The issue of research gaps can be even further generalized, 
as it does not only apply to epidemiological data. Many 
AOPs have been put together from the published literature. 
Mechanistic toxicology publications often examine one 
mechanistic step (i.e., one KER) or the link of one particular 
KE to an AO. However, few publications address an entire 
AOP, and thus there are often gaps of knowledge between 
some KEs of an AOP. Therefore, AOP developers are recom-
mended to consider the tailored Bradford Hill criteria while 
assessing newly postulated AOPs (Becker et al. 2015). Obvi-
ously, these are also important gaps that limit the applica-
tion of AOPs for hazard assessment, as the overall scientific 
confidence (strength) of the AOP is reduced, if not all con-
nections are supported by strong and preferably quantita-
tive exemplar data. This situation highlights the overall gaps 
in our knowledge and can guide future research in several 
areas: first, the causal relationship between the respective 
 KEupstream and  KEdownstream, starting from the MIE and lead-
ing to the AO. The quantitative aspects of these KERs at 
specific exposure levels will gain more and more importance 
in the future. Second, based on such quantitative data, the 
similarity between compounds with respect to AOP activa-
tion can be determined. Such similarity along an AOP can 
form an important basis for read across, as it adds valuable 
information to that of purely chemical similarity. Third, a 
new wave of research will go beyond the KE as such and 
address the relative importance of modulatory events. In all 
likelihood, there will be a fruitful interaction between the 
improved construction of an AOP and the clarification of 
general gaps of knowledge concerning modulatory events 
of AOP KEs. Filling these knowledge gaps is an important 
step toward the construction of quantitative AOPs (qAOP).
Design of mechanistic test methods
An important practical advantage of AOPs is that they allow 
to define test methods for KEs and that these results can in 
principle be related to classical apical end points of hazard 
assessment (AO) via the AOP definition, if sufficient knowl-
edge is available. Such tests provide, for example, a relevant 
way for the prioritization of relevant chemicals. This is of 
interest in early phases of drug development (Hartung 2017) 
and also in large-scale toxicity screens of chemicals. The 
data obtained in this way can be used as a decision base for 
further testing, for further development or for risk manage-
ment strategies. The vision is that MIE/KE-based test batter-
ies would substitute at some point classical end point testing. 
This strategy has been applied for instance in the area of skin 
sensitization and it is widely used in the area of genotoxicity 
(Basketter et al. 2012). An example from ecotoxicology is 
the use of vitellogenin modulation as a conclusive indica-
tor of estrogen-related endocrine disruption (Matozzo et al. 
2008).
The concept of mechanistic tests as filters for toxicologi-
cal decisions (also called ‘pre-tests’) has a long history. Pre-
tests were introduced more than 50 years ago in specific 
fields of toxicology, e.g., based on the knowledge that muta-
tions represent a key event on the path toward developing 
cancer (Bhattacharya 1948; Ames and Whitfield 1966). In 
the past decades, this approach has allowed for the waiving 
of numerous unnecessary in vivo carcinogenicity studies. 
For instance, when bacterial and mammalian cell mutagen-
icity tests result in clear-cut positive results, it is usually not 
necessary to perform a 2-year carcinogenicity study in rats 
or mice, because of the high probability of a positive result 
(Basketter et al. 2012).
Genotoxicity tests are an example for a selection of a KE 
common to many AOPs. Multiple MIE converge on the KE 
of DNA mutation or chromosome breaks. The design of tests 
for such KE is particularly efficient for early identification of 
safety hazards, as large groups of chemicals can be captured. 
It is likely that the first larger KE-based test batteries will 
strongly focus on such ‘promiscuous’ or ‘joint’ KEs (i.e., KE 
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that are common to various AOP). Another typical example 
is mitochondrial toxicity. It represents an easy-to-measure 
KE and is clearly linked to various AOs (Hamon et al. 2014; 
Wilmes et al. 2013; Limonciel et al. 2011). If a chemical 
reaches the toxicity target cells in a tissue at concentrations 
that compromise mitochondrial function, then there is a high 
likelihood that adverse effects would ensue at the cell and 
organ level. For this reason, mitochondrial dysfunction tests 
are being developed in many projects. A relevant goal of 
the immediate future is to define a comprehensive set of 
KEs measureable in vitro, which have adverse consequences 
when present in vivo. Examples include predictive systems 
of developmental toxicity mediated by chemicals that inhibit 
migration of neural crest cells (Zimmer et al. 2012, 2014; 
Smirnova et al. 2014; Nyffeler et al. 2017) that block neurite 
growth (Stiegler et al. 2011; Krug et al. 2013b) or compro-
mise the regulation of genes normally up- or downregulated 
during normal embryonic development (Krug et al. 2013a; 
Rempel et al. 2015). Other important examples are interfer-
ences with nuclear receptors and developmental signaling 
pathways (van der Burg et al. 2015a, 2015b; Bal-Price et al. 
2015a, b, 2017), the generation of oxidative stress (Schild-
knecht et al. 2009, 2011, 2017; Krug et al. 2014) and endo-
plasmic reticulum stress.
In the context of research on new chemical entities 
(drugs, pesticides, etc.), such early testing has been used to 
guide chemical design strategies: For instance, it implied 
the development of alternative structures, which have the 
same desired effect, while avoiding the toxic effect identi-
fied in mechanistic in vitro tests, an approach called Green 
Toxicology (Maertens et al. 2014; Crawford et al. 2017). A 
challenge of these is the adequate integration of metabolic 
activation and detoxification into the testing strategy to per-
form adequate in vitro-to-in vivo extrapolations (IVIVE). As 
a consequence, there is a need for relevant kinetic models to 
determine target tissue concentrations of chemicals (Tsaioun 
et al. 2016). If these issues are solved, organ toxicity may be 
predicted and animal experiments may be avoided.
Anchor point for computational toxicology predictions
There are multiple ways to use the information embedded 
in AOPs for toxicity predictions, and the development of 
such methods represents an emerging field. One exemplar 
approach is the identification of experimental test methods 
that are associated with KEs and in particular with MIEs. 
Then, large databases (e.g., Tox21) can be screened for 
detecting compounds that are hits in such assays. Such 
compounds are of particular concern, as they are likely to 
activate the respective AOP. A variant of this approach is 
the in silico screening of all new compounds in an industry 
(e.g., cosmetics and consumer products) against their inter-
action with all known MIEs of AOPs. According to this, 
compounds of unknown hazard can be assigned to vari-
ous concern levels (e.g., ‘high concern’ if they are likely to 
strongly activate several MIEs; or ‘low concern’ if no known 
MIE is activated). Based on this knowledge, chemicals could 
be classified according to their biological fingerprint (profile 
of biological activation). Notably, this approach will gain 
momentum and impact with increasing numbers of AOPs, as 
then a larger fraction of all possible hazards will be covered. 
A second example for exploitation of AOPs for computa-
tional toxicology may be based on transcriptome data. Most 
MIEs and KEs are associated to certain genes, e.g., if an 
MIE is ‘binding to the androgen receptor (NR3C4)’, then it 
is associated with the corresponding androgen receptor gene. 
Transcriptome mapping of toxicant responses also yields 
lists of genes. Computational and statistical methods can be 
used to probe for overrepresentation of certain genes among 
toxicant-induced transcriptome changes. This approach can 
be used to identify AOP-associated genes and develop new 
AOPs or improve existing ones, or to determine a potential 
mode of action from transcriptome data.
Recently, so-called cpAOPs (computationally predicted 
AOPs) have been described, which are built by integrating 
openly available HTS in vitro data and information on the 
disease phenotype (Oki and Edwards 2016). Further, map-
ping gene expression data onto disease data revealed inter-
esting new causalities via the use of network analyses. This 
approach aims to unravel mechanistic relationships merely 
from the available data, without any prior knowledge about 
a certain AOP. Thus, in the near future data science will 
likely offer a wealth of orthogonal strategies to biological 
approaches for building AOPs.
Improved predictions on toxic responses for humans 
by interspecies extrapolation
As mentioned above, the underlying mechanistic concept 
of AOPs has been in use for decades, although a different 
nomenclature was used (Leist et al. 2008). An important 
application in the past was to improve predictions on toxic 
responses for humans by interspecies extrapolation. The 
mechanistic understanding was also used to better under-
stand the basis of interindividual differences within human 
populations. An important example for the former point 
is the explanation why humans are relatively resistant to 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated tox-
icity, compared to certain mouse strains like C57BL6/N and 
certainly not as susceptible as guinea pigs (Hengstler et al. 
1998). More recent research has also shown that this species 
difference applies to developmental toxicity due to altered 
expression of the target for the MIE (Baumann et al. 2016; 
Bal-Price et al. 2015a; Gassmann et al. 2010). The con-
cept has also been used to explain why humans are several 
orders of magnitude less susceptible to tamoxifen-induced 
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carcinogenesis than rats and mice, and why humans are 
more susceptible to digitoxin compared to mice due to MIE 
interspecies differences regarding the inhibition of the Na/K-
ATPase (all cases reviewed in Hengstler et al. 1999). These 
examples demonstrate that understanding the mechanisms 
causing toxicity helped to extrapolate from animal models to 
humans. They also helped to understand the molecular basis 
of interindividual differences regarding the susceptibility of 
humans to toxic substances, e.g., by definition of genetic 
variants of genes relevant at various positions of the AOP 
chain (Hengstler et al. 1999). Important cases of species 
differences are found in the field of endocrine disrupters. 
Here, the targets are not altogether different, but relative 
expression levels and fine modulations of regulation show 
pivotal differences. In this field, a large step has been the 
design of human cell-based test batteries, involving an AOP 
structure and computational modeling to substitute existing 
animal tests, such as the uterotrophic assay (Casey 2016; 
Kleinstreuer et al. 2016, 2017).
Limitations and shortcomings at the present stage 
of AOP development
It was only 10 years ago that in 2007 toxicity pathways were 
suggested by the National Academy report (NRC 2007, Leist 
et al. 2008, Andersen and Krewski 2009) as a basis for risk 
assessment. Several related concepts, such as pathway of 
toxicity, the human toxome or biomarkers of toxicity (Blaau-
boer et al. 2012) arose from this idea. The specific AOP 
concept itself was only presented as recently as in 2010 by 
Ankley et al. (2010; Becker et al. 2015; Knapen et al. 2015; 
Wittwehr et al. 2017). Despite the rapid development since 
then, it should not be surprising that the AOP concept, and 
its handling by regulatory bodies, is still in a dynamic phase. 
This implies continuous optimizations and necessary adapta-
tions, also including a learning-by-doing process. To sup-
port the further development, it is important to highlight 
the advantages, but also to pinpoint areas that should be 
reconsidered and optimized. Finding the appropriate balance 
requires a continued discussion process and revision of the 
respective current state of knowledge and demands to the 
system. Awareness of potential weaknesses and understand-
ing of the respective reasons for them allows the optimal 
handling of the tool by various users. For this reason, some 
present weaknesses, perhaps to be amended soon, as well as 
others to be considered on the long term are listed below.
The assumptions of unidirectionality and linearity
Typically, AOPs are presented as a unidirectional chain 
of events from MIE over KEs to AO (Fig.  1) (Ankley 
et al. 2010). Moreover, the preferred mode of graphical 
presentation is a linear array of KEs. This has practical 
advantages, which are extensively discussed, e.g., by Ville-
neuve and colleagues (Villeneuve et al. 2014a, b). It has been 
clear to the developers of the concept that this unidirectional 
linearity is not always in agreement with biology. Especially 
degenerative processes often bear features of vicious circles 
(Schildknecht et al. 2017; Nicotera et al. 1999) or require 
multiple hits (Hengstler et al. 2012). Although users and 
developers of AOPs are aware of the problems, the ideal 
solution has not yet been found. Further developments will 
be necessary to make the AOP concept useful for all applica-
tions in regulatory toxicology. As a discussion starter, it is 
important to review briefly the alternatives to a linear and 
unidirectional AOP:
1. A toxicity pathway may involve positive or negative 
feedback loops. This situation is found quite frequently. 
For instance, one of the most important principles of 
metabolic regulation is negative feedback: the negative 
control of early steps by products of late steps. Positive 
feedback loops are typically found in the regulation of 
signaling pathways or in proteolytic cascades. This leads 
to an avalanche effect, once the cascade has been trig-
gered;
2. Non-linearity may occur in at least two major variants. 
Either the AOP bifurcates, or another pathway joins 
the AOP. An example of the former case is the recently 
established AOP on mitochondrial complex I inhibition, 
leading to parkinsonian motor deficits, where a bifurca-
tion leads to neuroinflammation as positively enhancing 
feedforward event (https://aopwiki.org/aops/3). Exam-
ples of the latter case are multi-hit events, where, e.g., 
ongoing DNA damage triggered by an electrophilic 
compound/metabolite, or by oxygen radicals, joins the 
path of events triggered by a tumor promotor;
3. An AOP may appear to be linear and unidirectional, but 
their nodes (KEs) get input not only from the upstream 
KEs, but also from various modulatory events. These 
inputs are integrated in complex (often not simply addi-
tive) ways (e.g., by allosteric regulation or by repair 
processes against damage), and the final outcome 
determines whether the next (downstream) KE is ever 
activated.
Especially, feedforward loops and pathway synergy can 
be hard to handle in a quantitative manner. Systems biol-
ogy has created tools to address these issues appropriately, 
but such approaches require quantitative modeling, and 
they are not reflected by simple arrow schemes. Non-linear 
multi-step processes are not only found in carcinogenesis, 
where they are well documented, but are also relevant 
to organ toxicity. Besides steatosis, and other forms of 
liver damage, many inflammation-related reactions are 
3487Arch Toxicol (2017) 91:3477–3505 
1 3
non-linear because of structural non-linearities (in addi-
tion to possible non-linearities in the quantitative rela-
tionship between two successive KEs). For instance, the 
experimental liver toxicant concanavalin A can activate 
lymphocytes. Lymphocytes can then activate Kupffer 
cells to produce tumor necrosis factor (TNF) and Kupffer 
cells can further activate lymphocytes. This sequence can 
lead to a strong enhancement of TNF release compared to 
direct Kupffer cell stimulation, and this huge augmenta-
tion has a key role in the ensuing liver damage (Gantner 
et al. 1996).
First, attempts have been undertaken to address the issues 
of linearity. For instance, a positive feedback loop has been 
incorporated into the complex I-parkinsonism AOP (Fig. 2) 
and a negative feedback loop into the cholestasis AOP 
(AOP-wiki Nr. 27) from deregulated transporter proteins 
back to bile acid accumulation. It has been acknowledged 
that a feedback response can be causally linked to the AO. 
If it is measureable and fits a linear sequence, the present 
rules allow it to be included as KE in the AOP (see e.g., 
https://aopwiki.org/aops/23); in other cases, new solutions 
are required. One of these novel approaches has been chosen 
by the developers of the protein alkylation-liver fibrosis AOP 
(Horvat et al. 2017). For the core AOP, they suggest a canon-
ical linear and unidirectional AOP (Fig. 3a), but also dis-
cuss that several steps are modulated by oxygen radicals and 
inflammation. Then they present a more complex scheme 
with feedback loops for the general overview (Fig. 3b). Per-
haps, one solution for the future will be a demand-driven 
practical approach to produce a series of AOP variants with 
differing levels of complexity, adapted to the respective 
application.
The new version of the AOPs User’s Handbook (in pro-
gress, but not yet published as of July 2017) will also open 
some new possibilities. It is stipulated that representation 
of branching in an AOP will be acceptable, especially when 
there are multiple KEs, causally linked to the MIE and AO 
that occur concurrently and likely act in concert to drive the 
downstream effects. In such cases, the various KEs do not 
have to be necessarily placed neatly into a single temporal 
sequence, because they effectively occur simultaneously. 
Likewise, it cannot necessarily be determined which of the 
concurrent KEs are most essential or critical, because there 
are multiple KEs (measurable biological changes) contrib-
uting jointly in an additive manner such that it cannot be 
effectively determined whether one could cause the pathway 
to progress without the other. This is contrasted with cases 
where KEs act independently such that one event or the 
other, alone, would allow progression toward the outcome.
Neglect of event modifiers in graphical displays
As detailed above, downstream KEs do not only get input 
from the upstream KEs, but from multiple other direc-
tions. In initial versions of the AOP guidance, there was 
more emphasis on such modulatory events, and the graphi-
cal display of modifiers as an integral part of the AOP was 
considered. The removal of modulatory events in graphical 
representations, as suggested by the current handbook and 
website procedures, has led to a simplified display, and this 
provides a faster and easier overview. However, the down-
side is that major biological information is lost from the 
display. It is stipulated in the handbook that this informa-
tion can be added as text. For instance, the information is 
Fig. 2  Example of a recently proposed AOP aiming to describe criti-
cal steps from binding of a toxicant to mitochondrial complex I to 
parkinsonian motor deficits. The schematic has been reproduced from 
the AOP website (http://aopwiki.org/aops/3). It exemplifies how a 
positive feedback loop has been incorporated into an AOP (KE5 feed-
ing back on KE4) that is thus non-linear. This was introduced as it is 
not possible on the basis of available data to clearly define whether 
KE4 or KE5 is more upstream. Strong scientific evidence supports a 
vicious circle at this position of the AOP
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captured in the “Quantitative understanding of the linkage” 
section of the KERs. The more completely and quantita-
tively the KERs and their potential modulating factors are 
described, the greater is the capacity to predict whether the 
severity of perturbation (in terms of dose, duration, timing, 
etc.) at the MIE will be sufficient to elicit the AO. However, 
it is nevertheless not optimal if pivotal inputs and control 
mechanisms of high relevance for an AO cannot be displayed 
Fig. 3  Comparison of a linearized AOP and a more complex scheme 
of the underlying biology. a Example of a recently proposed AOP 
aiming to describe critical steps from protein alkylation to liver fibro-
sis (reproduced from Horvat et al. 2017). The simple linearized form 
provides a clear and rapid overview of important events. However, 
modulatory events cannot be seen from such graphical presentations. 
For instance, there are several mechanisms that remove activated stel-
late cells and thus affect KE4. Liver fibrosis only occurs when these 
anti-fibrotic mechanisms are overwhelmed. In line with this, there is 
evidence from rodent experiments that all steps shown in this AOP, 
from protein alkylation over hepatocyte death, stellate cell activation 
and increased collagen deposition can be active without leading to 
liver fibrosis as the adverse outcome. This may have important impli-
cations for some regulatory applications of such an AOP. b Sugges-
tion of the same authors on how a more complex network of events 
may be visualized. Such steps may be taken when an AOP is further 
developed as quantitative AOP (qAOP)
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graphically. It is often argued that the description of KE and 
KER leaves all necessary options to add complex informa-
tion. However, this argument does not consider the fact that 
the choice between what is displayed graphically (and what 
most people will use as the main source of information) and 
what is presented ‘in text form only’ is a prioritization of 
information. Here, the likely user behavior must be consid-
ered; and it is probable that with the availability of hundreds 
of AOPs, the largest majority of users will not read all text 
(thousands of pages).
The graphical display rules convey the impression that a 
KE is always more important than a modifier. This assump-
tion can be biologically wrong, and the various modulatory 
factors may become more important than the KE itself. For 
instance, TNF may play a role in hepatotoxicity models (KE: 
TNF-induced apoptosis), but modifiers have such a huge 
impact that the toxicity is augmented 1000-fold by pretreat-
ment with galactosamine (Leist et al. 1996, 1997a, c, b), or 
the KE never takes place (independent of the amount of TNF 
and hepatocyte pre-sensitization) if, e.g., hepatocyte ATP is 
depleted (Latta et al. 2000). Another example is excitotoxic-
ity triggered by N-methyl-d-aspartate (NMDA) receptors, 
which is modulated by many orders of magnitude by the 
mitochondrial function and cellular energy state (Volbracht 
et al. 2001a, b; Leist et al. 1997a, b, 1998a; Leist and Nico-
tera 1997).
The concept of modulatory factors has been explored in 
depth in toxicology and pathology concerning the impor-
tance of genetic variants relevant to an AOP. Two examples 
illustrate that these can be more important than the actual 
threshold event. In carcinogenesis, a chemical can lead to 
DNA damage (KE) without further pathology (no AO). 
Notably, DNA damage is ongoing continuously without 
exposure to chemicals due to endogenously formed oxygen 
radicals. Yet, the high rate of DNA damage is not sufficient 
to trigger tumor formation. The activation of ‘modulatory’ 
oncogenes or the inactivation of tumor suppressor genes 
plays a major role in carcinogenesis, and this is not necessar-
ily part of the AOP (as downstream KE); rather, sometimes 
a chemical-independent modulatory event is determined by, 
e.g., genetic factors. The same importance of modulatory 
events is observed in an entirely different pathological set-
ting, involving mitochondrial failure. Toxicants can affect 
mitochondrial function, but also many endogenous events 
present a continuous challenge to mitochondria. Modulatory 
factors that change the threshold of mitochondrial failure, 
such as the large family of B cell lymphoma 2 (Bcl-2)-re-
lated proteins, determine in many cases whether toxicity will 
be induced or not. In the future, knowledge on mechanisms, 
together with detailed knowledge on modulatory factors 
that affect KE thresholds will be instrumental in extrapo-
lating data from in vitro systems to the human situation. 
This issue is currently tackled, although there is still a lot 
of work required to understand the complex stress signaling 
networks and other pathways affecting cell physiology in dif-
ferent culture conditions (Daneshian et al. 2016). Inevitably, 
KERs and modulatory factors affecting them will have to be 
experimentally assessed and confirmed by experimentation, 
using gene knockdown or chemical inhibitors.
Dealing with compensatory mechanisms
Compensatory mechanisms are a specific variant of modula-
tory factors, but they are so important in biology that they 
are highlighted here with particular emphasis. AOPs deal 
with damaging cascades, but are not optimized to deal with 
repair processes, regeneration and counter-regulation. Nota-
bly, the guidance handbook stipulates that all such processes 
are considered and described (in the ´Quantitative under-
standing of the linkage’ part of the KER judgment) during 
the establishment of the AOP. Especially in the considera-
tion of KERs, strong emphasis is to be put on the fact that an 
MIE progresses to the first KE only when all compensatory 
mechanisms have been overwhelmed and the AO is only 
reached when this is true for all steps. Once the AOP has 
been reviewed and established, such considerations are only 
accessible to those reading the background text in detail. 
For other users, all considerations of repair and compensa-
tion are lost in the graphical display. However, they play a 
crucial role, especially for chronic toxicities (Hengstler et al. 
2012). The prediction of the balance between damage and 
compensation will be key to the issue of defining adversity 
from simple test systems, and this research area therefore 
needs to be strongly fostered and supported. The potential 
issues will be illustrated using the example of the recently 
published, and above described, AOP protein alkylation 
leading to liver fibrosis. This AOP has been published on 
the AOP-wiki (https://aop.wiki.org/aops/38), and similar 
figures have been presented (Edwards et al. 2016; Oki and 
Edwards 2016) (Fig. 2). Briefly, this AOP states that protein 
alkylation leads to a sequence of hepatocyte death, Kupffer 
cell and stellate cell activation, increased production of the 
extracellular matrix and finally to bridging fibrosis.
The relevance of stellate cell activation for liver fibrosis 
was first reported more than 30 years ago and repeatedly 
reviewed (Bataller and Brenner 2005; Wynn 2008; Godoy 
et al. 2013). It is an AOP KE. According to the AOP, a 
sufficient level of protein alkylation in hepatocytes would 
suffice to trigger the series of critical events ultimately 
leading to liver fibrosis. However, this simple sequence of 
subsequent steps, one triggering the next, does not predict 
the AO with sufficient accuracy. The flaw can be illustrated 
by a simple experiment: administration of a hepatotoxic 
dose of protein alkylating compounds, e.g., acetaminophen 
(APAP, 300 mg/kg, i.p), (Fig. 4) or carbon tetrachloride 
 (CCl4, 1 g/kg, i.p.), (Fig. 5a) causes pericentral hepatocyte 
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death, followed by massive stellate cell activation and 
increased collagen production. Therefore, all key events 
shown in the AOP scheme (Fig.  3), hepatocyte death, 
Kupffer cell activation, and stellate cell activation are 
triggered, and their activation occurs to a massive extent. 
Approximately, 40% of all hepatocytes are killed and at 
least a similar fraction of all stellate cells becomes acti-
vated. However, despite the massive activation of all key 
events proposed in the recently published AOP, no liver 
fibrosis is induced (Fig. 5). Instead, a perfect regenera-
tion of functional tissue architecture is observed (Hoehme 
et al. 2007, 2010). Similarly, no liver fibrosis is seen fol-
lowing repeated injections of the same doses of APAP 
or  CCl4, if the intervals between the individual doses are 
long enough, e.g., 4 weeks, even if massive hepatocyte 
death and stellate cell activation are induced after each 
individual compound administration. What is the reason 
for the apparent discrepancy of such experimental findings 
and the published AOP? There are two important answers: 
(1) from the mechanistic perspective, the reason is that the 
AOP does not account for regeneration and compensation. 
In fact, the activated stellate cells are rapidly removed dur-
ing liver regeneration (Fig. 6). While a maximal number 
of activated stellate cells is seen around day 3 after the 
induction of liver damage, it takes only until day 6 for all 
of them to be removed. It is important to consider that 
removal of activated stellate cells represents an active 
process. The responsible mechanisms have been reported 
previously and include clearance by immune cells, e.g., 
macrophages (Duffield et al. 2005; Ramachandran et al. 
2012), apoptosis which can be induced by the activity of 
natural killer cells infiltrating the regions where stellate 
Fig. 4  Occurrence of massive hepatic death and stellate cell activa-
tion without ensuing necrosis. The images show livers of C57BL6/N 
mice at various time periods after a single intraperitoneal administra-
tion of 300  mg/kg paracetamol (APAP). The panels show the mac-
roscopic appearance of the livers (Grossly), hematoxylin and eosin 
staining (H&E), immunostaining with antibodies against α-smooth 
muscle actin (α-SMA) as a marker for activated stellate cells, immu-
nostaining with antibodies against F4/80 as a marker for infiltrating 
and tissue resident macrophages also named ‘Kupffer cells’ (F4/80) 
and Sirius red staining to visualize fibrosis (Sirius red). APAP causes 
massive pericentral necrosis visible in the H&E-stained slides at 12 h 
and 2 days. Two days after APAP intoxication, the entire pericentral 
necrotic area is occupied by activated stellate cells visualized by α-
SMA. However, 4  days after intoxication, the number of activated 
stellate cells is reduced and the tissue is completely cleared from 
activated stellate cells after 6 days. Particularly at day 4, infiltration 
of F4/80-positive macrophages is seen, which play a role in remov-
ing activated stellate cells. Sirius red staining demonstrates that no 
fibrosis is formed. The key message of this experiment is that massive 
hepatocyte death and massive stellate cell activation do not necessar-
ily lead to liver fibrosis
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cells have been activated (Radaeva et al. 2006; Tian et al. 
2013; Fasbender et  al. 2016), senescence of activated 
stellate cells which results in a phenotype with reduced 
fibrogenic activity and increased sensitivity to killing by 
immune cells (Krizhanovsky et al. 2008; Kim et al. 2013), 
as well as reversal of activated, collagen-producing stellate 
cells to a quiescent state (Kisseleva et al. 2012). Moreo-
ver, numerous studies have been published that describe 
the removal of the deposited extracellular matrix by pro-
teases (Duffield et al. 2005; Ramachandran et al. 2012; 
Ramachandra and Iredale 2012; Tacke and Zimmermann 
2014); (2) from a risk assessment point of view, the AOP 
should assume a certain time frame of repeated exposure 
(frequent, continued exposure, short intervals). Only in 
this case, e.g., twice weekly administration of hepatotoxic 
doses (Fig. 5b), fibrosis is formed.
Thus, the AOP may sometimes be right and sometimes it 
delivers inadequate predictions. A detailed examination of 
strengths and weaknesses, as exemplified here, may help to 
make the AOP more comprehensive. The studies displayed 
here suggest that a more universally applicable AOP of liver 
fibrosis must include pro- and anti-fibrotic mechanisms as 
well as exposure and timing conditions. An adverse out-
come, such as fibrosis, will occur only when pro-fibrotic 
processes exceed and exhaust anti-fibrotic mechanisms for 
a critical period of time.
In conclusion, those examples illustrate that an all too 
simple (linear, non-modulated) AOP concept may not agree 
Fig. 5  Lack of correlation of stellate cell activation and the degree 
of fibrosis. a The images show livers of C57BL6/N mice at various 
time periods after a single intraperitoneal administration of 1  g/kg 
 CCl4. Despite massive pericentral cell death (H&E) and stellate cell 
activation (α-SMA) at day 2, all activated stellate cells are removed 
until day 6 and no fibrosis is formed (Sirius red). Therefore, the 
situation is similar to that after acute APAP intoxication shown in 
Fig. 4a. b Administration of 1 g/kg  CCl4 twice weekly for 2 months. 
The images were taken 2, 4 and 6 days after the last dose of  CCl4. 
Interestingly, stellate cell activation is much weaker compared to the 
acute situation. Nevertheless, liver fibrosis occurs (Sirius red), which 
is not reversible within the studied time period and persists although 
the activated stellate cells are removed (α-SMA). The experiments 
show that formation of liver fibrosis is not sufficiently explained by 
the extent of activated stellate cells. A correct model must take into 
account whether anti-fibrotic mechanisms, such as removal of acti-
vated stellate cells and lysis of deposited extracellular matrix, are 
overwhelmed or still able to compensate pro-fibrotic mechanisms
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with experimental data. It is important to take into account 
that hepatocyte death and stellate cell activation represent 
important key events, although per se not inevitably caus-
ing liver fibrosis. It is out of question that humans should be 
protected from any exposure that causes hepatocyte death 
and stellate cell activation. Therefore, establishing in vitro 
systems that reliably predict these key events is of high rel-
evance. On the other hand, an AOP with “stellate cell activa-
tion” as a key event should not be interpreted in a way that 
lack of stellate cell activation guarantees non-toxicity, in this 
case no fibrosis. The descriptive AOP concept (as detailed 
above) may not be up to this challenge. For this reason, the 
concept of quantitative AOP (qAOP; a concept which is 
much more akin to systems biology) is being developed in 
parallel, and some of the descriptive AOPs of nowadays may 
be converted into qAOPs later on (Table 1).
Binning of events
Due to the limited information on what set of molecular 
events really contributes essentially to a given KE (like 
mitochondrial dysfunction), many KEs in AOPs are defined 
very broadly (synaptic dysfunction, hepatocyte injury, stel-
late cell activation, etc.). Thus, many different biochemical/
molecular events are put into ‘large bins’. Such bins can be 
as large as the whole field of neuroinflammation or mito-
chondrial failure, or altered intracellular proteolysis, each 
comprising hundreds of players and being covered by thou-
sands of articles. A KE is meant to define a given cellular 
state, but if the exact molecular change is not well defined, 
it actually comprises several cellular states and this may be 
problematic for the subsequent KER. The binning of several 
cell states into one KE is a helpful simplification for many 
purposes, but it makes quantification and computation in 
the sense of systems biology very difficult. Therefore, it will 
be important to explore in much more detail how far AOPs 
with large sets of KEs can be used for qualitative or semi-
quantitative hazard estimates. Technical artifacts are another 
consequence of the ‘binning’ approach in AOP networks. 
Apparently identical KEs (e.g., inflammation or mitochon-
drial dysfunction in various AOPs) may in fact be based on 
different biochemical mechanisms that have been put into 
the same bin, and this would lead to very different KERs. 
Binning is not only done for KEs, but also for MIEs. For 
instance, protein alkylation is considered as an MIE for liver 
fibrosis. However, there are several fundamentally differ-
ent ways to alkylate protein’s nucleophilic structures. Some 
agents preferentially target cysteine residues, while others 
prefer other targets, and the type of cellular damage and its 
downstream consequences are therefore different. Moreover, 
of course, other mechanisms besides protein alkylation may 
cause hepatocyte death followed by stellate cell activation 
and liver fibrosis. Therefore, the absence of experimental 
evidence for protein alkylation should not be misinterpreted 
in a way that the substance of interest will not cause fibrosis 
in vivo.
Dealing with multiple hit events
The linearity of AOPs suggests that only one MIE initi-
ates the chain of events that finally results in an AO. It is 















Healthy liver Fibroc liver cirrhoc liver
Fig. 6  Display of anti-fibrotic mechanisms. Removal of activated stellate cells by immune cell-mediated killing, senescence and reversion to a 
quiescent state represent some of the most important anti-fibrotic mechanisms
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mechanisms, or the initiation–promotion model in carcino-
genesis. A further example, acute-on-chronic organ fail-
ure (most frequently of the liver or kidney), represents an 
increasingly recognized entity encompassing an acute dete-
rioration of organ function in response to an acute event, 
which occurs only under conditions of a chronically stressed 
tissue (Jalan et al. 2016). All situations in which a KE is not 
a downstream consequence of an MIE, but an independent 
event, essential for pathology to happen, cannot easily be 
captured by an AOP, and the concept needs to be opened 
for such important pathological sequences (see Fig. 7 for 
overview). A typical scenario where multi-hit events occur 
is when one compound generates more than one toxicologi-
cally relevant metabolite. In such situations, each metabolite 
may induce different KEs. This may become critical, when 
those KEs synergize and contribute to the same AO. Espe-
cially, when the simultaneous occurrence of two KEs is a 
precondition to induce a specific AO, it will be challenging 
to represent this by a linear AOP. Likewise, AOP networks 
may be difficult to construct, if there is not an overlap of 
KEs, but rather a KE of one AOP acts as strong modifier 
of a KE in another AOP. An illustrative example is that of 
the nasal tumors induced by vinyl acetate in rats (reviewed 
in Hengstler et al., 2003). After inhalation, vinyl acetate is 
metabolized to acetic acid and acetaldehyde at sites of con-
tact, such as the olfactory epithelium. Acetic acid causes a 
pH decrease that, when exceeding critical thresholds, leads 
to cell death and replacement proliferation. The second 
metabolite, acetaldehyde, induces genotoxic effects, such 
as DNA–protein cross-links, chromosomal aberrations and 
sister chromatid exchanges, but not point mutations. Exten-
sive experimental work has shown that the genotoxic effect 
synergizes with pH-induced cell death, and this mechanistic 
knowledge has supported regulatory toxicology and identi-
fication of adequate threshold values. Long-term exposure 
to 600 ppm vinyl acetate causes a reduction in pH by 0.49 
units, which leads to olfactory (basal cell) degeneration and 
an increase in basal cell proliferation that is more than two-
fold above control levels (Hengstler et al. 2012). Physiologi-
cally based pharmacokinetic (PBPK) models indicate that 
inhalation of 600 ppm vinyl acetate leads to about 12 µg/
ml of acetaldehyde in olfactory epithelial cells. This is 
clearly above the concentrations that cause sister chromatid 
exchanges and chromosomal aberrations in in vitro tests. 
This matches the results of a carcinogenicity study where a 
significant increase in nasal tumors was observed in rats at 
600 ppm vinyl acetate. At 200 ppm of vinyl acetate, the pH 
Fig. 7  Illustration of linearity, unidirectionality, feedforward, feed-
back and modulatory events. a A linear AOP consists at least of 
one MIE (green), one KE (here two are shown; in white and yellow) 
and the adverse outcome (orange). b Linear AOPs can be combined 
to AOP networks with shared MIE and AO, as shown here, or with 
disparate MIE/AO and only one shared KE. c, d Some KEs may be 
strongly affected by modulatory factors (positive or negative). These 
are not usually displayed graphically. e An AOP-like sequence may 
appear linear on graphical display, but a positive feedback loop may 
indeed break unidirectionality. For modeling applications, this cor-
responds to a bifurcation (at a given KE, the continuation goes two 
directions (backwards and forwards). Note that in the graphical dis-
play, the AOP still looks like a linear (one-dimensional) array of 
events. Such features may, e.g., be observed in cell death signaling. 
f Another AOP-like sequence may contain a negative feedback loop. 
Such features are found in many metabolic pathways. g A positive 
feedback loop may occur in a non-linear sequence, as exemplified 
in Fig. 2. h An AOP may take a non-linear appearance, if it joins an 
endogenous, toxicant-independent event that is continuously ongoing 
and important for the AO to happen. For instance, tumor promotion 
may occur by phorbol esters, acting on protein kinase C (MIE), but 
they require continuously ongoing DNA damage. Several events in 
toxicology require more than one hit (e.g., classical initiation-promo-
tion-progression model of carcinogenesis) and are difficult to display 
as linear event with a single MIE at least if both events are triggered 
by the same chemical, or if one of the event is chemically independ-
ent (color figure online)
▸
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in the olfactory epithelium is reduced by approximately 0.25 
units, which leads to only mild olfactory degeneration and 
very weak replacement proliferation. Acetaldehyde concen-
trations in olfactory epithelial cells are 5.4 µg/ml according 
to the PBPK model and thereby still above concentrations 
that cause genotoxicity in vitro. In the carcinogenicity study, 
only one nasal tumor was observed, which was not statisti-
cally significant. 50 ppm vinyl acetate can be considered a 
NOAEL for both mechanisms—replacement proliferation 
as well as genotoxicity. This concentration causes a pH 
reduction of 0.08 units, which results in neither cell death 
nor replacement proliferation. The basal cell acetaldehyde 
concentration is modeled to be 1.7 µg/ml, which is below 
concentrations reported to cause genotoxicity in vitro. No 
nasal tumor is induced at this exposure level.
Acetaldehyde is a natural constituent of the body and is 
formed in endogenous metabolic processes, a fact that is 
relevant for risk evaluation. Normal, blood concentrations 
are in the range of 0.3 µg/ml (Hengstler et al. 2003). There-
fore, a very conservative argumentation would be that vinyl 
acetate exposure should be below levels at which acetalde-
hyde metabolically generated from vinyl acetate exceeds the 
endogenous concentrations of 0.3 µg/ml. This would be in 
the range of 1 ppm vinyl acetate. The mechanistic knowl-
edge from basic science briefly summarized in this section 
provides regulators with a basis to make informed decisions 
on adequate threshold values.
Trying to force this and similarly complex scenarios, 
where different MIE synergize to induce an AO into the 
schematic of a linear AOP (Fig. 1), does not seem to be ade-
quate. Presenting two MIE triggered by two metabolites that 
induce two different KEs may be more appropriate. Impor-
tantly, both KEs synergize with respect to the AO. Besides 
vinyl acetate, situations where different mechanisms have to 
be active simultaneously to induce an AO occur also outside 
the field of carcinogenicity (Jalan et al. 2016).
How to deal with effect duration
The text description of AOP elements allows for considera-
tions of effect duration or for delayed effects. However, the 
construction elements available do not visualize this, and the 
ideas on how this needs to be considered for semi-quantita-
tive or quantitative AOPs are still at a relatively basic level. 
There are many biological examples of the extreme impor-
tance of stress duration, independently of the overall stress 
intensity threshold. This principle was already formulated at 
the beginning of the twentieth century in the form of Haber’s 
rule (toxic effect = concentration of toxicant × exposure 
duration). An illustrative example has also been presented 
here (above, Fig. 4) with the experiments on liver fibrosis 
triggered by acetaminophen (APAP) or  CCl4. Single doses, 
or repeated doses with sufficient recovery time, do not lead 
to AO. However, liver fibrosis occurs if a certain frequency 
of hepatotoxic doses is exceeded; for example, 2 doses of 
1 g/kg  CCl4 per week will exceed this threshold (Fig. 5b). 
For applications of AOPs in risk assessment, formalization 
of the timing aspect appears important.
A specific feature of the timing aspect is not only the 
length of exposure (relevant in repeated dose toxicity), but 
especially in the area of developmental and reproductive 
toxicity (DART) the window of exposure, i.e., the exact 
phase of development in which exposure occurs. This is 
exemplified by the recently published AOP leading from 
topoisomerase inhibition and subsequent mixed lineage 
leukemia (MLL) gene rearrangement to infant leukemia 
(Pelkonen et al. 2017). In the suggested AOP, the MIE is 
called “in utero topoisomerase poisoning” to note the devel-
opmental period. Incorporation of such timing information 
into graphical displays should be further encouraged for 
all DART-relevant AOPs. An exact documentation of the 
timing aspect is also provided by work on stem cell-based 
developmental toxicity models, where small changes of the 
exposure window cause large differences ranging from pro-
nounced adverse effects to no effect (Balmer et al. 2012, 
2014; Balmer and Leist 2014; Shinde et al. 2016).
Open questions to be addressed 
and communicated concerning construction, 
assessment and handling of AOPs
With a complex system such an AOP, which is still at the 
beginning of its development, two types of question often 
arise. First, there are still open issues that need to be dis-
cussed, consolidated, or developed further. Second, some 
concept features are easily missed or misunderstood, or are 
applied and promoted by stakeholders in ways originally not 
foreseen. Both issues are important for harmonized use and 
understanding. These issues are not necessarily strengths 
or weaknesses, but discussing them is helpful to appropri-
ately use and implement the AOP concept in an in vitro-
based hazard evaluation. Some of these features are briefly 
addressed in this chapter.
The issue of non‑toxicity
AOPs are a tool for hazard assessment. It is widely accepted 
that a compound likely to activate an AOP is of higher con-
cern than compounds activating no AOP. However, going 
one step further, the issue is less clear. What does this mean 
in quantitative terms? What does concern really mean? Also 
very important: is absence of evidence really evidence of 
absence concerning toxicity? The answers to these questions 
are far beyond the scope of this review, but the discussion 
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appears important and two of the arguments (coming from 
very different angles) are briefly highlighted here.
In some discussions, the real or purported flaws of AOPs 
are used to increase doubt about the potential toxicity of 
compounds. Some discrepancies, matters of incompleteness, 
or species issues in AOPs are highlighted. Moreover, the 
apparent lack of absorption, distribution, metabolism, and 
excretion (ADME) information is criticized and any such 
‘AOP imperfections’ are used to suggest that association of 
a given compound with an AOP is not relevant to its hazard. 
Such arguments are found for instance in public consulta-
tions on new AOPs, mostly promoted by representatives of 
the chemical industry.
An entirely different type of discussion arises from the 
question of which conclusions can be drawn from the acti-
vation or non-activation of AOPs. In this context, it is par-
ticularly important to avoid the misconception that failure to 
activate an AOP, a group of AOPs, or even all documented 
AOPs means non-toxicity of a compound. The AOP con-
cept states that an individual AOP makes no statements on 
‘non-toxicity’, and this question is thus neither a strength nor 
weakness of AOPs. This must also be understood in the light 
of defining criteria of AOPs: They are compound agnostic 
and do not involve the toxicokinetic phase. For statements 
on non-toxicity, a defined compound always needs to be 
considered, and ADME plays a key role. Thus, at present, 
the arguments on this issue are pretty clear. The situation 
may however change in the future, when many more AOPs 
will be established, and the toxicological community will 
feel that a large percentage of all possible AOPs in a given 
area, or in the entire field of toxicology, have been described. 
Tests for all MIEs/KEs may become available, and these 
may allow a comprehensive experimental access to the ques-
tion whether a compound activates any AOPs at a relevant 
concentration. In such a situation, failure of a chemical to 
activate any of the many tests may be interpreted as a low 
likelihood to be hazardous to humans. However, at present, 
the state of the art is far away from such a situation.
Notably, this issue is not to be confused with the use of 
AOPs as a basis to develop an integrated testing strategy 
(ITS), or an integrated approach to testing and assessment 
(IATA). In this case, testing of AOP KEs is combined with 
other information, and the KE tests are chosen in such a 
way as to broadly cover many modes of action leading to 
a widely accepted and relatively general adverse outcome. 
The most prominent example is testing for skin sensitization 
(NTP 2017), and similar approaches are in preparation for 
testing of estrogenicity. In such cases, negative results would 
have toxicological and regulatory importance, although only 
within the small range of questions covered by the ITS/
IATA.
An interesting question is how to handle AOPs that are 
driven by threshold or non-threshold mechanisms. For 
threshold mechanisms, the situation is quite clear. If an MIE 
occurs at levels that are too low to induce a KE, no AO can 
be expected. The scenario becomes more challenging when 
no threshold mechanism has been demonstrated, which is 
for example the case for some types of DNA adducts (MIE), 
mutations (KE) and tumors (AO). In this case, one has to 
assume that in the presence of MIEs all other steps (KE) 
are also active leading to the respective AO, or at least an 
increased risk of AO. This underlines the importance of dif-
ferentiating whether an AO is caused by threshold or non-
threshold mechanisms (Bolt et al. 2004; Oesch et al. 2000, 
2001; Hengstler et al. 2003).
Quantification of KEs/KERs; threshold setting
The example of the first practically applied AOPs, i.e., the 
AOP developed for skin sensitization, shows how difficult 
it is to move from a qualitative AOP (as it has been depos-
ited) to something with clear quantitative thresholds that 
can be used in a prediction model for risk assessment and 
quantification. Until now, there is no consensus prediction 
model available, although the KE tests have been extensively 
validated and a vast amount of quantitative work has been 
invested in this area. One of the difficulties in such a quan-
titative use of AOPs is the setting of appropriate thresholds, 
or the establishment of respective mathematical rules that 
connect the sufficient perturbation of  KEupstream with the trig-
gering of  KEdownstream. As sequences are not all linear, and as 
they are subject to modulatory factors, complex non-linear 
relationships can arise, and the parametrization of such mod-
els, as well as their validation, is both difficult and requires 
large data sets.
An illustrative example has been given above for vinyl 
acetate: the threshold setting for a KE assay of one metabo-
lite would depend on the pH, and the latter is determined by 
another metabolite, in addition to multiple other factors. In 
this situation, an AOP-guided risk assessment would most 
likely be useful in cases of very high compound exposure 
(far beyond a likely threshold), but uncertainties would rise 
if lower concentrations, relevant to human exposure are 
considered, and the tool may not be suitable for regulatory 
decisions in complex situations of synergistically interact-
ing pathways.
Another example is found above, with fibrosis triggered 
by alkylating agents. The extent of hepatocyte death is a 
KE threshold of relevance. This is illustrated by the fact 
that healthy livers continuously experience low levels of 
hepatocyte death events, which leads to permanent low-level 
replacement proliferation. If for example, a healthy adult 
C57BL6/N mouse receives a single injection of bromod-
eoxyuridine (BrdU) 1 h prior to preparation, approximately 
0.5% of all hepatocytes stain BrdU positive. This illustrates 
that hepatocyte death and replacement proliferation occur 
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continuously to a low extent in healthy livers. These hepato-
cyte death events are quantitatively below critical thresh-
olds, since mice (and humans) do not develop liver fibrosis 
throughout an entire lifetime unless affected by liver dis-
eases. Thus, this KE is always ongoing without triggering 
the AO, unless additional modulatory factors change, and a 
lot of work will be required for the exact threshold setting.
Can toxicodynamics be separated from toxicokinetics 
and metabolism?
The AOP concept states that AOPs only predict hazard, 
but not risk. Moreover, the aspects of ADME are explic-
itly not considered by AOPs. This may seem logic within 
the AOP system, as they are ‘compound agnostic’: Only 
compounds can have toxicokinetic behaviors, but not a path-
way. However, in the weight-of-evidence process to support 
AOP KERs, example chemicals are essential, and for such 
examples it is hard to neglect their individual pharmacoki-
netic properties. Considering this, it is not clear whether 
the toxicokinetic and toxicodynamic phase can always be 
clearly separated. For instance, one of the best-known neu-
rotoxicants is MPTP. Its selective toxicity to neuronal sub-
populations, but not to astrocytes, can only be explained by 
metabolic and distribution steps (Schildknecht et al. 2015). 
Vice versa, the MPTP metabolite MPP + is toxic in vitro to 
neurons (Schildknecht et al. 2013), but hepatotoxic (and not 
neurotoxic) in vivo.
Another complicated situation arises, if one compound 
generates several metabolites, which trigger various interact-
ing AOPs. Moreover, some AOP KEs may affect the metabo-
lism/distribution of a compound that triggers the respective 
AOP; or in other words, activating or detoxifying metabo-
lism does not necessarily have to occur exclusively prior 
to the first KE (although this is often the case), but can be 
between two KEs and represent a necessary precondition for 
a downstream KE. Examples are tumor precursor cells (e.g., 
preneoplastic nodules of the liver) that express higher levels 
of detoxifying enzymes and give preneoplastic cells a selec-
tion advantage which facilitates the next steps on the path 
to cancer. A clinically relevant example is ‘acute-on-chronic 
liver failure’. Here, chronic administration of a compound (or 
a chronic disease state) may alter the levels of metabolizing 
enzymes that render the organ susceptible to ‘second hits’. 
A special example is toxic cholestasis. Here, the initial KE 
is damage to cholangiocytes, leading to obstructions of the 
biliary tract. This leads to increased bile salt concentrations 
in the blood. As a mechanism of this KE, it has been sug-
gested that obstructions in parts of the biliary tract induce an 
increase of the inner surface area of interlobular bile ducts by 
surface corrugation as well as looping and branching, which 
increases their reabsorption capacity for bile salts (Vartak 
et al. 2016; Jansen et al. 2017). As an adaptive response 
to increased bile salt concentrations in blood, hepatocytes 
downregulate enzymes involved in bile salt synthesis and 
transporters that convey bile salts into hepatocytes (Jansen 
et al. 2017). This is accompanied by down-regulation also 
of xenobiotic metabolizing enzymes, which may render the 
liver susceptible to ‘second hits’. Moreover, also with mol-
ecules undergoing metabolism and complex transport pro-
cesses, a strict separation of the ADME phase and AOP may 
be somewhat artificial; strictly (and theoretically) speaking, 
the AOP begins with an MIE triggered by the concentration 
of the respective compound or its metabolite at the target 
site of the MIE, but in many cases such concentrations are 
hard to measure. Moreover, great care needs to be taken 
to avoid establishment and exemplification of AOPs on the 
basis of chemicals used at unrealistically high concentrations 
(e.g., in in vitro systems). At present, the experience gained 
with AOPs is too limited to decide whether the strict separa-
tion between AOP and toxicant ADME can and should be 
maintained. The question needs to be borne in mind and the 
situation monitored accordingly. It should also be consid-
ered that separation of metabolism and toxicokinetics from 
toxicodynamics has been introduced because of practical 
circumstances. Since specialized tools are required, ADME 
is usually analyzed in different departments than toxicody-
namics. However, from a biochemical or cell biology point 
of view, this separation is rather arbitrary. A glutathione 
molecule binding to a substrate or an epoxide binding to the 
N7 position of guanine both represent nucleophilic additions 
and it may be considered as arbitrary to accept only one of 
them as KE. Therefore, one potential alternative may be to 
include metabolic activation or inactivation of parent com-
pounds in the form of a special KE. Such processes of drug 
metabolism are measurable not only in vivo, but relatively 
reliably also in vitro, determine the outcome of toxicity in 
a decisive way and describe important system states. The 
technically relatively easy introduction of metabolism as a 
special KE into AOPs would open attractive additional pos-
sibilities. On the one side, the compound agnostic nature of 
the AOPs would not be compromised if metabolic activa-
tion/detoxification is introduced as general KE. Addition-
ally, important compound-related aspects and interspecies 
differences could be correctly described; importantly, a 
KE ‘metabolism/detoxification’ could be analyzed in vitro. 
Such currently untapped potential of the AOP concept is 
exemplified by the case of the heterocyclic amine MeIQx 
(2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline), which is 
present in cooked and fried meat. MeIQx is carcinogenic in 
rats, but does not induce hepatocellular cancer in cynomol-
gus monkeys (reviewed in: Hengstler et al. 1999). Without 
knowledge of the responsible molecular mechanisms, this 
discrepancy between the two animal species made human 
risk evaluation difficult. The relevant metabolism to gener-
ate the genotoxic electrophile has been explored in depth: 
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MeIQx is metabolically activated to a nitrenium ion. The 
latter then binds covalently to DNA. This MIE initiates 
a complex series of KE, such as mutations, activation of 
oncogenes, inactivation of tumor suppressor genes and com-
promised cell cycle control, which finally leads to cancer 
(AO) (reviewed in Hengstler et al. 1999). Knowledge of the 
metabolism and of the hazard cascade (AOP) could now be 
combined in two different ways.
The solution suggested by most relevant stakeholders of 
the AOP concept would be to combine the different types 
of information in an IATA to be used for risk assessment or 
for species comparison and extrapolation. In this context, 
the information could be used that human hepatocytes form 
the phase I metabolite hydroxylamine (a precursor of the 
nitrenium ion) in a similar way to hepatocytes isolated from 
rat strains that are susceptible to MelQx carcinogenicity; in 
cynomolgus monkeys, this metabolic pathway shows only 
little activity. Therefore, humans have to be expected to be 
similarly susceptible to MeIQx-induced carcinogenicity 
as some rat strains, but differ from cynomolgus monkeys 
that are resistant. In the past, such an observation would 
have puzzled scientists, since the phylogenetic proximity 
of humans to monkeys may intuitively lead to the opposite 
expectation.
Another solution would be to add a KE of ‘electrophile 
formation’ before the MIE or it could be integrated as part 
of the MIE. This would at present be against the rules and 
concept of AOP. It needs to be observed and compared for 
many cases to come in the near future whether there would 
be an advantage in a more overlapping approach of ADME 
and hazard assessment, especially considering the issue 
that AOPs do not refer to specific compounds while ADME 
somehow has to be compound specific.
Review process and updating
There are two quality control issues to be considered: (1) 
the establishment of the AOPs on the OECD website; (2) 
the publications on specific AOPs in scientific journals. 
The journal peer review process has mainly been designed 
for primary original research work. It puts a high time 
constraint on prominent researchers and only works since 
this is considered a mutual service, linked to the benefit 
of knowing at an early time point what the competitors are 
doing. These incentives are not given for the reviewing of 
a large and complex document as an AOP. Therefore, it is 
unlikely that the major experts in the field will be willing 
to invest sufficient time in it. This will reduce the quality 
of the review process. Moreover, the one-way, single-blind 
review system is not suitable for reviewing extremely com-
plex weight-of-evidence information as happens in AOP. 
Discussion and feedback are required, just as the involve-
ment of broad sets of experts. This makes the publication 
of AOPs in scientific journals challenging and problem-
atic. Another problem with journal publications is that 
the articles are immovable, while knowledge continuously 
advances. Both, for the review and for updating of content, 
a blog-like system would be more suited. Concerning jour-
nal publications, new solutions will need to be found, as it 
is important to inform the broad scientific community also 
in journals on key advances in the field of AOPs. Some 
review journals have already implemented a discussion 
process of reviewers and authors, and few of them have 
also documented this discussion.
Similar considerations apply to the AOP website (AOP-
wiki). An AOP developed within a project of the AOP 
work program at the OECD undergoes a rigorous and 
transparent internal and external review process. If suc-
cessfully completed, this ends with endorsement and pub-
lication in the OECD series on AOPs (Delrue et al. 2016). 
The establishment and accreditation of an AOP is thus 
already now a multi-stage process with several discussion 
and feedback rounds. However, it is difficult to track ver-
sion history and discussion arguments later on. There is 
also no clear plan for scheduled updating of AOPs and 
for conflict management. At present, the highly controlled 
process is very structured, but this may prevent important 
and valuable input from many scientists who shy away 
from the administrative effort. It remains also unclear how 
the hundreds of AOPs would be kept updated. A radical, 
but clean solution would be to tag AOP with an expiry date 
and if they are not reviewed, e.g., within a 5-year period, 
they would be automatically labeled as obsolete.
Quality assurance and validation of AOPs
Closely linked to the above question is the issue of qual-
ity assurance and validation of an AOP in its function as 
a toxicological tool (e.g., as a basis for a testing strat-
egy). At present, AOPs are based on scientific literature. 
However, the current “reproducibility crisis” describes the 
increasing realization that scientific literature is too often 
not reproducible (Hartung 2013), may contain contradic-
tive data, or may not be sufficiently transparent and clear 
to the reader (Leist et al. 2010, 2012). Moreover, most of 
the relevant data are derived from animals, and the trans-
ferability to human biology is often not clear (Leist and 
Hartung 2013). This stresses the importance of using ele-
ments of evidence-based toxicology (Hartung 2009) such 
as quality scoring, systematic review, risk-of-bias analysis, 
and meta-analysis for the quality control and validation 
of AOPs. There is not yet agreement on how to apply and 
formalize this; some discussion can be found in the context 
of mechanistic validation (Hartung et al. 2013a).
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One procedure for simple steps and complex events
Some AOPs are very straightforward and the information 
contained is relatively ‘trivial’. For instance, an aromatase 
inhibitor leads to aromatase inhibition and thus to a lack 
of hormones generated by aromatase (http://aopwiki.org/
aops/25). Similarly, an estrogen receptor agonist increases 
systemic estrogen signaling. These examples may help to 
break the ice and promote the field. However, it is not yet 
clear whether such examples will really help us in defining 
and solving the problems of building a complex test strategy. 
Note that ‘trivial’ is not meant as a derogatory term here, but 
refers only to the complexity of the construct.
It is important to recall here that one major goal of the 
AOP framework is to provide an overarching concept to 
improve our in vitro testing strategies. It is well established 
that aromatase inhibition will compromise estrogen syn-
thesis and may therefore lead to reproductive dysfunction. 
Therefore, it is clear that aromatase inhibitors may cause 
reproductive dysfunction, when present at sufficiently high 
concentrations at their target sites. However, besides aro-
matase inhibition, many more mechanisms may cause repro-
ductive dysfunction. A challenge for the future will be to 
establish batteries of in vitro assays that cover as many as 
possible relevant mechanisms that besides aromatase inhi-
bition may also cause reproductive dysfunction. The more 
complex the mechanisms that lead to an adverse effect, e.g., 
the development of steatosis or neurodevelopmental distur-
bances, the larger will this challenge become. In these cases, 
more complex forms of presenting AOPs and AOP networks 
may be required. Alternatively, it could be that dealing with 
more complex pathologies is something entirely different 
and cannot be attained by simple upscaling of linear small 
steps. It may require completely different approaches and 
concepts. We do not know this at present, and it is important 
to better define areas where AOPs have particular strengths 
and areas, where it is not clear how well the concept works. 
In this context, it is important to remember that the concept 
always has to be seen in combination with a defined appli-
cation, if its suitability is judged. AOPs for complex events 
have their justification also now already for instance to sort 
the available information (Hartung et al. 2012, 2017).
First evidence has been presented that high-throughput 
transcriptomics may be helpful to populate sAOPs with data 
that allow decisions and predictions (Jennings  2013). For 
instance, it has been found that specific AOs are associated 
with relatively similar gene expression responses, even if the 
MIE are diverse. An example is hepatotoxicity, where incu-
bation of primary human hepatocytes with relatively high 
numbers of compounds (n = 148) has shown that a stereo-
typical expression response (of the same set of up- or down-
regulated genes) is induced by numerous compounds known 
to be hepatotoxic in humans, even if these compounds act 
by different molecular mechanisms (Grinberg et al. 2014). 
For development of test methods, this observation may be of 
critical relevance; instead of analyzing a multitude of MIEs, 
it may be sufficient to measure a set of ‘biomarker genes’ if 
their deregulation is strictly associated with a set of distinct 
KEs that all lead to the same AO. However, implementa-
tion of this concept still requires a better understanding of 
the causal relationships between molecular initiating events, 
deregulation of ‘biomarker genes’ for KEs and the occur-
rence of AO.
How can the hazard‑based system of AOP be integrated 
with toxicokinetics in overall risk assessment?
In the late 1920s, JW Trevan’s work aided the introduc-
tion of the lethal dose 50  (LD50) test (Trevan et al. 1927). 
Although considered crude today, it was a major step at 
the time, as it provided the first quantitative measure to 
compare the toxicity of different substances. Quantitative 
dose–response relationships remain a core principle of toxi-
cology, where the dose (estimated or quantified) is related to 
a particular quantifiable adverse response, the most severe 
being death, as in the  LD50 assay. When cell cultures began 
to be applied to chemical testing in the 1960s, the  LD50 test 
was recapitulated using various types of cytotoxicity assays, 
from trypan blue exclusion to the MTT assay. Later, this 
became a bit more sophisticated in that we could discrimi-
nate between apoptosis and necrosis. However, none of it 
really helped with the prediction of human risk in real-world 
exposure scenarios as: (1) very little mechanistic insight was 
forthcoming, (2) there was often a serious over- or under-
estimation of the actual exposure concentration, (3) often 
the actual tissue concentrations remained unknown and (4) 
many of the in vitro systems did not represent the normal 
physiology of the parent tissue, which can affect the uptake, 
extrusion, metabolism, or molecular targets. Today, the  LD50 
in in vivo experiments plays only a minor role and more 
quantile and information-rich measurements are used, such 
as tissue structure, behavior and biomarkers. The in vitro 
counterpart is almost exclusively involved in discovery and 
verification of the mode of (adverse) action of compounds.
Regardless of the chemical (or nanoparticle) that can 
cause an adverse effect, it first has to reach the target tissue 
and reach concentrations high enough to cause a perturba-
tion, which could also be an activation or inhibition of a pro-
cess, and the perturbation must be of a certain strength and 
duration to cause an imbalance in cellular homeostasis. Only 
if the initial perturbation (or MIE) is substantial enough, it 
will trigger adaptive and/or maladaptive responses, which 
will alter cellular biology and in time lead to an adverse 
outcome.
Thus, there are two major challenges for the use of AOPs 
in risk assessment: (1) quantification of the kinetics (what 
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the biological system does to the chemical over time) to 
determine the internal concentration at the MIE site; and (2) 
quantification of KE thresholds that lead to downstream KEs 
(what the chemical does to the system over time) (Wilmes 
et al. 2013, 2015). In this context, it is important to note 
that KEs may be measured indirectly through biomarkers. 
Many of these biomarkers may indicate a KE, but are not 
implicated in the AOP progression themselves and thus are 
by definition no KEs.
Concerning the issue of toxicokinetics, one challenge 
that remains is to be able to model the oral doses that lead 
to these critical concentrations, because the possibilities of 
pharmacokinetic modeling are still limited due to uncertain-
ties. In this context, modeling and simulation approaches 
offer a way to bridge the relative chemical exposure seen 
in the in vitro system and in the target organ in vivo (Fisher 
et al. 2017). In the in vitro system, a number of factors need 
to be considered to relate the nominal (applied) concentra-
tion to the concentration that is actually driving the toxic 
response. These include binding of the chemical to lipids 
and proteins in the cell culture medium, partition between 
the medium and the headspace of volatile chemicals, par-
titioning into and binding to cellular constituents, as well 
as binding to plastic in the cell culture system. All of these 
processes will act to decrease the free (unbound) concen-
tration in the in vitro system. A number of mathematical 
models have been developed to consider these various fac-
tors and allow the free concentration in the in vitro system 
to be calculated. PBPK models have been used to predict 
the concentrations of chemicals achieved in the different tis-
sues of the body following exposure by different routes (e.g., 
oral, dermal and inhalation; Bois et al. 2010). Traditionally, 
PBPK models have been built to describe the measured tis-
sue concentration versus time profile in animals and then 
adapted to predict concentration in human tissues. Over 
recent years, the development of in vitro–in vivo extrapola-
tion (IVIVE) techniques to predict drug clearance together 
with mechanistic models to predict tissue distribution (Pou-
lin and Theil 2002) has enabled direct prediction of concen-
trations in humans and has led to a more widespread use of 
PBPK models (Rostami-Hodjegan 2012), including the use 
of such models to support regulatory decision-making in the 
pharmaceutical industry. Applying a systems approach to 
PBPK models where information on the biological system 
and chemical-specific properties are separated makes it pos-
sible to use the PBPK model to simulate exposure scenarios 
in different human subpopulations. For instance, the physi-
ology can be changed to reflect the expected physiology 
(e.g., tissue composition, blood flow, enzymatic makeup of 
chemical metabolizing enzymes) in individuals of different 
ages (i.e., pediatric or geriatric subjects) and the simulated 
exposures compared to those expected in a healthy, young 
adult population (Polasek et al. 2013).
Demonstration that the techniques applied to pharmaceu-
tical compounds can also be successfully used to predict 
the in vivo tissue and plasma concentrations of chemicals 
in humans from a broader chemical space together with an 
assessment of the uncertainty associated with the predic-
tions would enable these IVIVE-PBPK techniques to be 
more widely applied in chemical risk assessment. Currently, 
all pharmacokinetics and quantitative hazard information, 
including modulatory factors and considerations of quan-
titative thresholds, is integrated in the context of the IATA 
concept (Tsaioun et al. 2016).
How to deal with species differences
AOPs consider taxonomic applicability, but in practice much 
of the weight-of-evidence information is derived from vari-
ous animal models and the species transferability (extrapola-
tion to human situation) is in most cases not exactly known 
(Leist and Hartung 2013). However, this lack of knowledge 
of species transferability is not an inherent limitation of the 
AOP concept; it is rather a consequence of a lack of adequate 
data. Rather than being a disadvantage, the establishment of 
MIEs and KEs is a precondition of a thorough interspecies 
comparison. If in vitro systems with human and animal cells 
are available that allow analysis and generation of in vivo 
relevant data of the most critical MIE or KE, a comparison 
between species becomes possible. In the past, this principle 
has already been used extensively, for example to understand 
interspecies differences in the toxicity of TCDD, tamoxifen 
or others. Given the multitude and variability of target spe-
cies, interspecies differences are even more pronounced in 
ecotoxicology.
How to deal with pathway plasticity
The AOP concept aims to link MIE via a strictly defined 
series of KEs to AO. Then, the overall idea is that chemical 
hazard would be evaluated, based on knowledge of which 
AOP is triggered by a given substance. Although MIE are 
not known for the majority of chemicals, such informa-
tion may be obtained using comprehensive test batteries. 
Although this concept appears straightforward, the complex-
ity underlying the different possible responses of organisms 
to chemicals should not be underestimated, as they often 
do not follow a single pre-defined path. The most trouble-
some confounder is that the path may change depending 
on pathological situations. For this reason, not only simple 
screen systems are used, but also complex in vitro models 
that allow several pathological features to be monitored at 
the same time. On this basis, the objective of the project is 
to build new AOPs/AOP networks, ideally including quan-
titative information and attempting to fill important gaps of 
knowledge. For instance, interlobular bile ducts respond to 
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cholestasis by elongation and branching, as well as corruga-
tion of their inner surface and upregulation of bile salt carri-
ers, which altogether enhance their capacity to reabsorb bile 
salts from the duct lumen and transport them into the neigh-
boring portal vein (Vartak et al. 2016). This protects chol-
angiocytes from too high concentrations of bile salts in the 
lumen of ducts, while simultaneously leading to increased 
blood concentrations of bile salts, an effect that is further 
enhanced by a blockage in the basolateral uptake of bile salts 
from the blood of liver sinusoids into hepatocytes during 
cholestasis (Jansen et al. 2017). Overall, the liver is pro-
tected from bile salt toxicity at the expense of higher blood 
concentrations, which after some time may lead to kidney 
toxicity. Similar diversions of pathways are known from the 
cell death field (Leist and Jäättelä 2001). For instance, a 
standard AOP may have caspase activation as KE (Gerhardt 
et al. 2001; Schierle et al. 1999; Hansson et al. 2000). When 
caspases are inhibited, the AOP does not stop, but new con-
nections, not initially active, are formed, and e.g., calpains, 
cathepsins or the proteasome are activated as alternative 
proteases (Foghsgaard et al. 2001; Volbracht et al. 1999, 
2001a, b; Hirt et al. 2000). This may involve the switch 
from mitochondria to lysosomes as sub-cellular target and 
is modified by multiple factors such as cellular chaperones 
(Fehrenbacher et al. 2004; Hansson et al. 2003; Nylandsted 
et al. 2002). Apart from altered proteolytic pathways, stress 
response pathways are responsible for altering the transcrip-
tional program in an attempt to redress the original perturba-
tion and reinstate cellular homeostasis (Jennings et al. 2013). 
Thus, a certain KE may cause negative feedback loops due 
to induction of stress response pathways, and the cellular 
regulation and the basis for AOP may be strongly altered.
From AOPs to quantitative AOPs (qAOP)
As stated above, AOP have different uses, many of them not 
requiring quantitative data. A future perspective is that next-
generation AOPs may also be applied in risk assessment of 
chemicals. For this purpose, quantitative thresholds need 
to be known. It is at present not clear how this will exactly 
be achieved. The AOP handbook states that some regula-
tory applications “will require that quantitative relationships 
between KEs be defined”. Quantifying certain KERs might 
prove to be a complex task, especially if the KEs in ques-
tion are in different biological domains, for example if one 
is at the transcript level and the other is at an enzyme activ-
ity level or organelle function. More detailed experimental 
evidence might be needed to better define the quantitative 
relationship of the two KEs. When the molecular interac-
tions will have been sufficiently elucidated, simple equations 
or more complex mathematical models could be applied. 
Indeed, such activity is being supported by another closely 
related OECD initiative, the Effectopedia. Effectopedia is 
defined as ‘an open-knowledge and structured platform able 
to display quantitative information on AOPs. It represents 
a collaborative tool designed to facilitate the interdiscipli-
nary efforts for delineating AOPs in an encyclopedic manner 
with greater predictive power.’ While many AOPs will be 
developed, it is likely that KEs and KERs will be shared 
and thus will be interchangeable modular components. Thus, 
the development of mathematical models for KERs can be 
deployed across several AOPs, increasing their value. One 
such example is the development of systems biology models 
for the Nrf2 pathway (Hamon et al. 2014).
An important precondition for qAOP is knowledge on 
basic homeostatic processes, which are supposed to be per-
turbed by toxicant exposure. In a dynamic process such as 
liver steatosis, for example, there is no hope of developing 
a correct qAOP if we do not have a detailed understanding 
and description of fatty acid balance in hepatocytes. This is 
where toxicology meets general systems biology and coop-
eration with other disciplines is particularly helpful. An 
approach of only exposing cells to toxicants is not sufficient 
to feed the information requirements of qAOPs. In addition, 
information on gene and metabolic regulatory networks and 
signaling pathways will be required. In conclusion, moving 
from AOPs to qAOPs would represent an important pro-
gress, but its implementation remains a challenging future 
perspective.
Perspectives and outlook: the low and the high 
hanging fruits
The AOP concept represents an important research oppor-
tunity and has helped to integrate molecular mechanisms 
into the field of regulatory toxicology. First applications 
of AOPs are emerging, but it appears as if there is still a 
long way to go until AOP-based hazard assessment based 
on in vitro MIE and KE testing will replace the current toxi-
cological approaches. Currently, it cannot be expected that 
AOPs assembled only on the basis of historical research not 
specifically designed for AOP development will be suffi-
cient for the regulation of chemicals. A dedicated research 
program to specifically confirm and validate AOPs and to 
add quantitative information on KERs is required. There is 
however an expectation that the AOP conceptual framework 
would help in pushing through a mechanistic shift in risk 
assessment by making use of all available information in a 
weight of evidence approach and/or forming the basis for a 
mechanistically driven testing strategy. In the short term, it 
is also expected that the framework will be used as a scaffold 
for developing guidance for complex hazard characteriza-
tion, providing a mechanistic contextualization of apical end 
points of concern.
3501Arch Toxicol (2017) 91:3477–3505 
1 3
There are relatively low hanging fruits in this field of 
research that can be readily reached. These are mainly 
in the areas of priority setting and pre-screening to pro-
vide alerts for downstream testing or implementing tiered 
approaches in the risk assessment of chemical substances 
instead of relying exclusively on large, expensive and 
sometime poorly predictive in vivo regulatory studies. For 
this purpose, full quantitative chains of events are not nec-
essarily needed. What is required is individual KEs with 
a high plausibility value (with respect to a link to an AO) 
that can be studied in vitro in a concentration-dependent 
manner. Examples are compromised migration of neu-
ronal precursors or compromised mitochondrial functions. 
Alternatively, interference with important nuclear recep-
tors may be probed with a comprehensive test battery. In 
a regulatory context, the information from such KE-based 
testing can then be used to prioritize chemicals for further, 
more complex testing. Similarly, such mechanistic tests 
are often very informative for in-house decision-making 
in pharmaceutical and chemical industries to discard toxic 
compounds early in development. Moreover, first informa-
tion can be obtained on relevant internal concentrations 
associated with adverse effects.
The next years are likely to bring profound changes and 
progress in this field. It will be exciting to see how work 
on the AOP platform can help to both fill in data (on exist-
ing and new AOPs) and shape the concept. In this sense, a 
revised version of this review published at regular intervals 
in the future could be a valuable approach to document and 
follow the developments.
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